9.620USD-0.93%Mkt Cap: 255.18M USDP/E: —Last update: 2026-06-01
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NX…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap255.18M USD
Enterprise Value233.49M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.44M USD
Revenue/Share—
Last Price9.620 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.16
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B18.19
EPS (TTM)-1.31
EPS (Forward)-0.96
52W Range
5.55052% of range13.34
52W High13.34 USD
52W Low5.550 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-143.61%
ROA-83.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.01M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3.59%
Net Debt-25.13M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio2.27
Quick Ratio2.25
Book Value/Sh0.5360 USD
Cash/Share0.9470 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)16.80 USD
Target Range10.00 USD – 20.00 USD
# Analysts5
Ownership
Shares Out.26.53M
Float15.47M
Insiders41.61%
Institutions18.23%
Short Interest
Short Ratio15.9d
Short % Float9.15%
Short % Out.5.38%
Shares Short1.43M
Short (prev mo.)1.54M
Technical
SMA 509.100 (+5.7%)
SMA 2007.691 (+25.1%)
Beta-0.12
S&P 52W Chg27.94%
Avg Vol (30d)96.31K
Avg Vol (10d)130.60K
Technical Indicators
RSI (14)46.7
MACD0.2731
MACD Signal0.4678
MACD Hist.-0.1947
BB Upper12.35 USD
BB Middle10.47 USD
BB Lower8.595 USD
BB Width35.89%
ATR (14)0.7334 USD
Vol Ratio (20d)0.54x